[Congressional Bills 119th Congress]
[From the U.S. Government Publishing Office]
[H.R. 6130 Introduced in House (IH)]
<DOC>
119th CONGRESS
1st Session
H. R. 6130
To amend title XVIII of the Social Security Act to provide for Medicare
coverage of blood-based dementia screening tests.
_______________________________________________________________________
IN THE HOUSE OF REPRESENTATIVES
November 19, 2025
Mr. Buchanan (for himself and Mr. Tonko) introduced the following bill;
which was referred to the Committee on Energy and Commerce, and in
addition to the Committee on Ways and Means, for a period to be
subsequently determined by the Speaker, in each case for consideration
of such provisions as fall within the jurisdiction of the committee
concerned
_______________________________________________________________________
A BILL
To amend title XVIII of the Social Security Act to provide for Medicare
coverage of blood-based dementia screening tests.
Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the ``Alzheimer's Screening and Prevention
Act of 2025'' or the ``ASAP Act''.
SEC. 2. MEDICARE COVERAGE OF ALZHEIMER'S DISEASE AND RELATED DEMENTIAS
EARLY DETECTION SCREENING TESTS.
(a) Coverage.--Section 1861 of the Social Security Act (42 U.S.C.
1395x) is amended--
(1) in subsection (s)(2)--
(A) in subparagraph (JJ), by striking the semicolon
at the end and inserting ``; and''; and
(B) by adding at the end the following new
subparagraph:
``(KK) Alzheimer's disease and related dementias early
detection screening tests (as defined in subsection (nnn));'';
and
(2) by adding at the end the following new subsection:
``(nnn) Alzheimer's Disease and Related Dementias Early Detection
Screening Tests.--The term `Alzheimer's disease and related dementias
early detection screening test' means a test furnished to an individual
for the detection of the pre-symptomatic and early stage of Alzheimer's
disease or related dementias on or after January 1, 2028, that--
``(1) is cleared under section 510(k), classified under
section 513(f)(2), or approved under section 515 of the Federal
Food, Drug, and Cosmetic Act; and
``(2) is--
``(A) a genomic sequencing blood or blood product
test; or
``(B) such other equivalent test, including a
single-analyte test, blood test analysis of cell-free
nucleic acids, multiplex panel test, whole genome
sequencing, protein expression, whole exome, whole
transcriptome, and medical imaging (which are based on
blood, blood products, tissue, urine or other
biospecimen), as the Secretary determines appropriate
in providing results comparable to those obtained with
a test described in subparagraph (A).''.
(b) Payment.--Section 1833(h)(1)(A) of the Social Security Act (42
U.S.C. 1395l(h)(1)(A)) is amended by inserting ``Alzheimer's disease
and related dementias early detection screening tests under section
1861(nnn) and'' after ``including''.
<all>